ArticleHuman vaccines & immunotherapeutics2013
Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design.
Article in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 76 citations in OpenAlex.
- Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66Influenza and other respiratory viruses · 2020Trial
- H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.The Journal of clinical investigation · 2016Trial
- Does human homology reduce the potential immunogenicity of non-antibody scaffolds?Frontiers in immunology · 2023Review
- Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice.Human vaccines & immunotherapeutics · 2022Article
- The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.NPJ vaccines · 2022Article
- Kinetic of the Antibody Response Following AddaVax-Adjuvanted Immunization with Recombinant Influenza Antigens.Vaccines · 2022Article
- Chikungunya Virus Vaccine Development: Through Computational Proteome Exploration for Finding of HLA and cTAP Binding Novel Epitopes as Vaccine Candidates.International journal of peptide research and therapeutics · 2022Article
- Top Down Computational Approach: A Vaccine Development Step to Find Novel Superantigenic HLA Binding Epitopes from Dengue Virus Proteome.International journal of peptide research and therapeutics · 2021Article
- Influence of the H1N1 influenza pandemic on the humoral immune response to seasonal flu vaccines.PloS one · 2021Article
- Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.PLoS biology · 2020Article
- Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge.Human vaccines & immunotherapeutics · 2020Article
- Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products.Human vaccines & immunotherapeutics · 2020Article
- Maternally-Derived Antibodies Protect against Challenge with Highly Pathogenic Avian Influenza Virus of the H7N3 Subtype.Vaccines · 2019Article
- Anti-H7N9 avian influenza A virus activity of interferon in pseudostratified human airway epithelium cell cultures.Virology journal · 2019Article
- Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.Frontiers in immunology · 2019Article
- CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.Immunological reviews · 2018Review
- 220 mutation in the hemagglutinin of avian influenza A (H7N9) virus alters antigenicity during vaccine strain development.Human vaccines & immunotherapeutics · 2018Article
- T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response.Human vaccines & immunotherapeutics · 2018Review
- Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity.Clinical and vaccine immunology : CVI · 2017Article
- Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
A new avian-origin influenza virus emerged near Shanghai in February 2013, and by the beginning of May it had caused over 130 human infections and 36 deaths. Human-to-human transmission of avian-origin H7N9 influenza A has been limited to a few family clusters, but the high mortality rate (27%) associated with human infection has raised concern about the potential for this virus to become a significant human pathogen. European, American, and Asian vaccine companies have already initiated the process of cloning H7 antigens such as hemagglutinin (HA) into standardized vaccine production vehicles. Unfortunately, previous H7 HA-containing vaccines have been poorly immunogenic. We used well-established immunoinformatics tools to analyze the H7N9 protein sequences and compare their T cell epitope content to other circulating influenza A strains as a means of estimating the immunogenic potential of the new influenza antigen. We found that the HA proteins derived from closely related human-derived H7N9 strains contain fewer T cell epitopes than other recently circulating strains of influenza, and that conservation of T cell epitopes with other strains of influenza was very limited. Here, we provide a detailed accounting of the type and location of T cell epitopes contained in H7N9 and their conservation in other H7 and circulating (A/California/07/2009, A/Victoria/361/2011, and A/Texas/50/2012) influenza A strains. Based on this analysis, avian-origin H7N9 2013 appears to be a "stealth" virus, capable of evading human cellular and humoral immune response. Should H7N9 develop pandemic potential, this analysis predicts that novel strategies for improving vaccine immunogenicity for this unique low-immunogenicity strain of avian-origin influenza will be urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.